Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists compare rare tumors to improve care

NCT ID NCT07429851

Knowledge-focused Sponsor: European Institute of Oncology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at medical records from 34 people with advanced, well-differentiated high-grade neuroendocrine tumors in the lung, thymus, or pancreas. The goal is to see if these tumors behave differently and how they are treated. By comparing outcomes, researchers hope to find better ways to manage these rare cancers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better understand how to diagnose and treat these rare tumors, leading to more tailored care.
What could go wrong
This is a small, observational study that only looks back at past data, so it cannot prove what treatments work best. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 34 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Histologically confirmed diagnosis of thymic, pulmonaRy and pancreatic well differentiated high grade neuroendocrine tumors(Ki-67 \> 20% according to WHO 2022)

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed diagnosis of well-differentiated high grade neuroendocrine tumor (Ki-67 \> 20% according to WHO 2022) performed or reviewed by a NEN-dedicated pathologist. * Primary tumor site:thyme, lung and duodenum-pancreas NETs. * Advanced stage of tumor disease and Any number of lines of therapy * Sufficient available clinical data on diagnosis, treatments, outcomes. Exclusion Criteria: * Poorly differentiated neuroendocrine carcinomas (NECs), GEP NET G1/G2, pulmonary carcinoid with Ki-67 \< 20%. * Diagnosis of mixed neuroendocrine non-neuroendocrine neoplasms (MiNENs) * Inadequate or unavailable tumor tissue for molecular analysis. * Incomplete clinical records or follow-up. * Other primary sites, except lung or pancreas.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neuroendocrine carcinoma of lung are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neuroendocrine neoplasm pulmonary large cell neuroendocrine carcinoma thymic neuroendocrine carcinoma well-differentiated thymic neuroendocrine carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neuroendocrine carcinoma of lung Neuroendocrine carcinoma of thymus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • European Institute of Oncology

    RECRUITING

    Milan, Italy, 20141, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.